Modeyso is the first and only approved treatment for recurrent H3 K27M-mutant diffuse midline glioma in patients aged one ...

The company is streamlining its global workforce as part of a multi-year cost-cutting strategy, while raising its 2025 ...

XtalPi and DoveTree collaborate on a groundbreaking $6 billion drug discovery partnership, merging AI technology with ...

With AI expected to play a significant role in drug approvals, how can companies build data sets that are ready for AI?

Chai Discovery secures $70 million to revolutionize AI-driven drug discovery, enhancing antibody design and accelerating breakthroughs in medicine.

The supplemental New Drug Application is supported by data from the Phase II TRANSCEND FL trial (NCT04245839), which showed ...

The deal brings the FDA-approved neuroblastoma therapy Danyelza (naxitamab-gqgk) to SERB Pharmaceuticals and advances its ...

Rick Richmond is a senior partner with Kirkland & Ellis LLP.

HHS is winding down mRNA vaccine development, impacting contracts with major pharma companies and resulting in nearly $500 ...

Bryan A. Liang, M.D., Ph.D., J.D., is executive director, Institute of Health Law Studies, California Western School of Law, and co-director, San Diego Center for Patient Safety, University of ...

Sanofi secures exclusive rights to develop plozasiran in Greater China, enhancing treatment options for hypertriglyceridemia ...

Ajovy becomes the first-and-only calcitonin gene-related peptide agonist approved for pediatric patients aged six to 17 years ...